All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
13 results for "Cancer" and "Brain and Spine Cancers" and "Brain and Spine Cancers"
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
This study is for persons with recurrent glioblastoma that has failed to respond to or has come back after standard radiotherapy and Temozolomide treatment. The overall goal of this study is to develop Gallium Maltolate (GaM), an experimental drug, as a new oral treatment for patients with glioblastoma brain tumors whose tumor has relapsed after initial treatment or has progressed despite initial treatment.
Protocol No
IIT-CONNELLY-GBM-GAMAY
Sub Category
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Protocol No
JOUNCE-JTX-8064-101
Optimizing NeuroCOgnition with Whole Brain Radiation Therapy (WBRT) using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole Brain Radiation Therapy for Brain Metastases
This project is being done to test a new technique called pulsed reduced dose-rate
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
Protocol No
IIT-SAEED-ONCO-RT
Sub Category
Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)
This project is being done to to assess the efficacy of substituting Pulsed Reduced Dose
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Protocol No
IIT-STRAZA-PRORADGLIO
Sub Category
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This clinical trial tests an investigational drug, STP705, that has shown through laboratory experiments to silence TGF-1 and COX-2 gene expressions, enzyme proteins believed to speed cancer growth in some cancers, which may result in tumor shrinkage when administered.
Protocol No
SIRNAOMICS-SRN-705-005
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Protocol No
ALLIANCE-N0577-CODEL
Sub Category
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance in Small Cell Lung Cancer
Protocol No
NRG-CC003
Sub Category
Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Protocol No
NRG-BN003
Sub Category
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Protocol No
ECOG-EAF151
Sub Category
Glioblastoma Adaptive, Global, Innovative Learning Environment
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Protocol No
GCAR-GBM-AGILE
Sub Category
Phase III Trial of Post-surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
Single Fraction SRS Compared with Fractionated SRS for Resected Metastatic Brain Disease
Protocol No
ALLIANCE-A071801
Sub Category
Genomically-Guided Treatment Trial in Brain Metastases
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Protocol No
ALLIANCE-A071701
Sub Category
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
SRS vs. HA-WBRT for 5-15 newly diagnosed brain mets
Protocol No
CCTG-CE7
Sub Category